Agenus rises on new drug development collaborations

Circio Holding ASA

31/05/2022 16:14

** Shares of Agenus Inc  AGEN.O  rise 7.9% to $1.74
    ** AGEN enters three new clinical collaborations for the
development of its cancer drug candidates  urn:newsml:reuters.com:*:nGNX3DnYvn
    ** New partnerships with cancer drug developers Targovax,
Oxford BioTherapeutics and Immunogenesis double the current
number of clinical collaborations, says AGEN
    ** Collaborations are meant to test AGEN's drug candidates,
including botensilimab and balstilimab, with other agents to
develop immunotherapy combos for a range of cancers - AGEN
    ** Combination studies are being sponsored and executed by
collaborators, with AGEN providing drug supply and scientific
support, says co
    ** Stock down 46% YTD, including session moves

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))